Medication topics
Mercaptopurine articles covering 6-MP immunomodulator treatment, safety monitoring, combination therapy, and IBD decisions. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
5 articles
The study connects a genetic regulator (PACSIN2) and Rac1 signaling to cellular responses to mercaptopurine, a drug used in IBD, offering a possible explanation for why some patients experience thiopurine-related gut...
Thiopurines are commonly used in IBD (azathioprine, 6-mercaptopurine). This review links these drugs — especially 6-thioguanine — to liver microvascular injury that can lead to portal hypertension, which may present...
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
